Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription Articles published in BJU Int Retrieve available abstracts of 158 articles: HTML format

Single Articles

April 2026
1. FU MZ, Packiam VT, Byrne J
   Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
   BJU Int. 2026 Apr 8. doi: 10.1111/bju.70271.
   PubMed    
   
   
   
2. KUMAR V, Kant R
   Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
   BJU Int. 2026 Apr 6. doi: 10.1111/bju.70268.
   PubMed    
   
   
   
3. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
   Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Manageme
   BJU Int. 2026 Apr 6. doi: 10.1111/bju.70230.
   PubMed     Abstract available
   
   
   
4. SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
   Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
   BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
   PubMed     Abstract available
   
   
   
5. BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
   Is there still a role for ureteric frozen section analysis during radical cystectomy?
   BJU Int. 2026;137:659-666.
   PubMed     Abstract available
   
   
   
6. DAY E, Bizzarri FP, Waine E, Martin R, et al
   Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
   BJU Int. 2026;137:708-715.
   PubMed     Abstract available
   
   
   
7. PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
   Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
   BJU Int. 2026;137:684-689.
   PubMed     Abstract available
   
   
   March 2026
8. HJORT PB, Jensen JB, Ernst A
   Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
   BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
   PubMed     Abstract available
   
   
   
9. YE T, Tura B, Abbotts B, Zeegers MP, et al
   Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications.
   BJU Int. 2026 Mar 23. doi: 10.1111/bju.70247.
   PubMed    
   
   
   
10. SLUSARCZYK A, Scilipoti P, Contieri R, Krajewski W, et al
    Refining BCG-failure classifications in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70231.
    PubMed     Abstract available
    
    
    
11. 
    Correction to "Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer".
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70248.
    PubMed    
    
    
    
12. SATHIANATHEN N, Perera M, Ischia J, Lawrentschuk N, et al
    Use of MRI in the diagnosis of bladder cancer: a health economic analysis.
    BJU Int. 2026 Mar 18. doi: 10.1111/bju.70243.
    PubMed    
    
    
    
13. ROESSLER N, Miszczyk M, Gontero P, Dematteis A, et al
    Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
    BJU Int. 2026 Mar 16. doi: 10.1111/bju.70214.
    PubMed     Abstract available
    
    
    
14. BRYAN RT, Patel K, Ward DG
    The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
    PubMed    
    
    
    
15. FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
    Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
    PubMed     Abstract available
    
    
    
16. AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
    Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
    BJU Int. 2026;137:536-546.
    PubMed     Abstract available
    
    
    February 2026
17. HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
    Aligning bladder cancer research with patient needs: an update on research priorities.
    BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
    PubMed    
    
    
    
18. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
    Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
    PubMed     Abstract available
    
    
    
19. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
    Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
    BJU Int. 2026;137:323-331.
    PubMed     Abstract available
    
    
    
20. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
    Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
    BJU Int. 2026;137:270-281.
    PubMed     Abstract available
    
    
    January 2026
21. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
    BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
    PubMed     Abstract available
    
    
    
22. ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
    Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
    PubMed     Abstract available
    
    
    
23. DI BELLO F, Gallioli A, Cannoletta D, Mancon S, et al
    Intravesical recurrence after therapeutic ureteroscopy for upper tract urothelial carcinoma: a meta-analysis.
    BJU Int. 2026;137:26-35.
    PubMed     Abstract available
    
    
    
24. MIEDERER M, Pretze M, Abbate E, Hartig A, et al
    Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
    BJU Int. 2026;137:166-172.
    PubMed     Abstract available
    
    
    December 2025
25. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
    Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
    PubMed     Abstract available
    
    
    
26. MENNES J, Akand M, Benijts R, Baekelandt L, et al
    Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
    PubMed     Abstract available
    
    
    November 2025
27. 
    Correction to "Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer".
    BJU Int. 2025 Nov 24. doi: 10.1111/bju.70090.
    PubMed    
    
    
    
28. PACE KJC, Kwong JCC, Randhawa H, Ringa M, et al
    Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 19. doi: 10.1111/bju.70085.
    PubMed     Abstract available
    
    
    
29. ABDULMAJEED A, Bekiroglu F, Aydin A, Laguna P, et al
    Guidelines adherence in non-muscle-invasive bladder cancer: a global survey of 3595 participants.
    BJU Int. 2025 Nov 18. doi: 10.1111/bju.70079.
    PubMed     Abstract available
    
    
    
30. RHODES AC, McClintic KA, Witt E, Nwosu I, et al
    Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 3. doi: 10.1111/bju.70060.
    PubMed     Abstract available
    
    
    
31. BRANDT SB, Korner SK, Milling RV, Nielsen NK, et al
    Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).
    BJU Int. 2025;136:858-865.
    PubMed     Abstract available
    
    
    
32. MASTROIANNI R, Chiacchio G, Tuderti G, Brassetti A, et al
    Stapled vs totally handsewn robotic intracorporeal neobladder: perioperative and functional outcomes.
    BJU Int. 2025;136:866-871.
    PubMed     Abstract available
    
    
    October 2025
33. MCELREE IM, Steinberg RL, Hougen HY, Mott SL, et al
    Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Oct 22. doi: 10.1111/bju.70044.
    PubMed     Abstract available
    
    
    
34. CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al
    Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
    BJU Int. 2025;136:728-737.
    PubMed     Abstract available
    
    
    
35. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    External validation of the Uromonitor(R)-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.
    BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010.
    PubMed     Abstract available
    
    
    
36. PAYNTER JA, Doherty Z, Qin KR, Pilcher D, et al
    Outcomes after cystectomy in Australian rural and metropolitan hospitals by intensive care admissions.
    BJU Int. 2025;136 Suppl 2.
    PubMed     Abstract available
    
    
    September 2025
37. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
    Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
    PubMed     Abstract available
    
    
    
38. FAZILI A, Jazayeri SB, Rose KM, Guske C, et al
    Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
    BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
    PubMed     Abstract available
    
    
    
39. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    PubMed     Abstract available
    
    
    
40. RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al
    Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
    BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
    PubMed     Abstract available
    
    
    August 2025
41. ZAURITO P, Scilipoti P, Longoni M, Viti A, et al
    The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905.
    PubMed     Abstract available
    
    
    
42. DEY L, Rautiola J, Akre O, Egevad L, et al
    Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883.
    PubMed     Abstract available
    
    
    
43. DE ANGELIS M, Scilipoti P, Santangelo A, Longoni M, et al
    The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates.
    BJU Int. 2025;136:336-343.
    PubMed     Abstract available
    
    
    
44. BEN-DAVID R, Pellegrino F, Mehrazin R, Thomas J, et al
    Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy.
    BJU Int. 2025;136:321-328.
    PubMed     Abstract available
    
    
    July 2025
45. LONGONI M, Scilipoti P, Zaurito P, Moschini M, et al
    Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867.
    PubMed    
    
    
    
46. HOF J, Vermeulen S, Richters A
    Biased associations between number of BCG instillations and outcome in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16866.
    PubMed    
    
    
    
47. VON DEIMLING M, Furrer M, Bianchi A, Pichler R, et al
    Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer.
    BJU Int. 2025 Jul 9. doi: 10.1111/bju.16851.
    PubMed     Abstract available
    
    
    
48. TEMPO J, Felemban S, Qin KR, Perera M, et al
    Radical cystectomy mortality in older patients: a systematic review and meta-analysis.
    BJU Int. 2025;136:19-31.
    PubMed     Abstract available
    
    
    June 2025
49. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
    What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
    PubMed     Abstract available
    
    
    
50. FERRO M, Catellani M, Bianchi R, Fallara G, et al
    Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16828.
    PubMed     Abstract available
    
    
    
51. ERAKY A, Ben-David R, Hug B, Kolanukuduru KP, et al
    Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel.
    BJU Int. 2025 Jun 15. doi: 10.1111/bju.16827.
    PubMed     Abstract available
    
    
    
52. HANEY CM, Studier-Fischer A, Geissler ME, Ohlmeier J, et al
    Indocyanine-guided ureter resection for radical cystectomy - a systematic review and meta-analysis.
    BJU Int. 2025;135:908-917.
    PubMed     Abstract available
    
    
    
53. AMPARORE D, De Cillis S, Colombo M, Garzena V, et al
    TYTOCARE home telemonitoring device after radical cystectomy to optimise postoperative outcomes.
    BJU Int. 2025;135:960-968.
    PubMed     Abstract available
    
    
    May 2025
54. KWONG JCC, Pace K, Al-Daqqaq Z, Chelliahpillai Y, et al
    Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
    BJU Int. 2025 May 26. doi: 10.1111/bju.16793.
    PubMed     Abstract available
    
    
    
55. VAN HATTUM JW, Remmelink MJ, Nuijens ST, de Ruiter BM, et al
    A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer.
    BJU Int. 2025 May 22. doi: 10.1111/bju.16767.
    PubMed     Abstract available
    
    
    
56. LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
    Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study.
    BJU Int. 2025 May 21. doi: 10.1111/bju.16780.
    PubMed     Abstract available
    
    
    
57. BOSVELD J, Nguyen TQ, Boormans JL, Witjes JA, et al
    The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study.
    BJU Int. 2025;135:766-774.
    PubMed     Abstract available
    
    
    April 2025
58. NUIJENS ST, van Hoogstraten LMC, Terpstra NB, Beeren I, et al
    The impact of treatment for muscle-invasive bladder cancer on health-related quality of life.
    BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736.
    PubMed     Abstract available
    
    
    
59. BRYAN RT, Patel P, Kennish SJ, Catto JWF, et al
    Improving the pathway to correct treatment for patients with muscle-invasive bladder cancer: exploring the myths around the BladderPath trial.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16728.
    PubMed    
    
    
    March 2025
60. COLLETT G, Bashford T, Whitehead NJ, Kazimierska E, et al
    Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army.
    BJU Int. 2025 Mar 22. doi: 10.1111/bju.16678.
    PubMed    
    
    
    
61. TREVISANI F, Floris M, Longoni M, Rosiello G, et al
    Acute kidney disease after radical cystectomy for bladder cancer: a new onco-nephrological view.
    BJU Int. 2025 Mar 21. doi: 10.1111/bju.16696.
    PubMed     Abstract available
    
    
    
62. ROLDAN FL, Ingelmo-Torres M, Mercader C, Figueras M, et al
    Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16697.
    PubMed     Abstract available
    
    
    
63. CHOWDHURY D, Apolo AB, Jiang DM, Skinner EC, et al
    Understanding patient perspectives in the management of their muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16695.
    PubMed     Abstract available
    
    
    
64. RAUTIOLA J, Bjorklund J, Ben-David R, Skokic V, et al
    Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder cancer.
    BJU Int. 2025 Mar 4. doi: 10.1111/bju.16691.
    PubMed     Abstract available
    
    
    
65. 
    Advances in the management of high-risk localised muscle invasive bladder cancer.
    BJU Int. 2025;135:364-365.
    PubMed    
    
    
    
66. STRUCK JP, Moharam N, Leitenberger A, Weber J, et al
    An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.
    BJU Int. 2025;135:446-455.
    PubMed     Abstract available
    
    
    
67. BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
    Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes.
    BJU Int. 2025;135:473-480.
    PubMed     Abstract available
    
    
    February 2025
68. TILLU N, Ben-David R, Skokic V, Rich JM, et al
    Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 20. doi: 10.1111/bju.16686.
    PubMed     Abstract available
    
    
    
69. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 18. doi: 10.1111/bju.16675.
    PubMed     Abstract available
    
    
    January 2025
70. BEEREN I, Meijer H, van der Heijden AG, Aben KKH, et al
    Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665.
    PubMed     Abstract available
    
    
    
71. KLUGER N, van der van der Bent SAS
    Tattoos as a risk factor for bladder cancer: a call for cohort studies.
    BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
    PubMed    
    
    
    
72. OLAH C, Sichward L, Hadaschik B, Darr C, et al
    Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
    PubMed     Abstract available
    
    
    
73. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
    BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645.
    PubMed     Abstract available
    
    
    
74. PFAIL J, Capellan J, Passarelli R, Kaldany A, et al
    National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
    BJU Int. 2025;135:140-147.
    PubMed     Abstract available
    
    
    
75. JOHN JB, Collins M, Eames S, O'Flynn K, et al
    The carbon footprint of the perioperative transurethral resection of bladder tumour pathway.
    BJU Int. 2025;135:78-87.
    PubMed     Abstract available
    
    
    December 2024
76. LONGONI M, Di Bello F, Rodriguez Penaranda N, Falkenbach F, et al
    Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
    BJU Int. 2024 Dec 12. doi: 10.1111/bju.16622.
    PubMed     Abstract available
    
    
    
77. HAILE ES, Lone Z, Shin D, Nowacki AS, et al
    Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16606.
    PubMed     Abstract available
    
    
    
78. PACIOTTI M, Diana P, Gallioli A, De Groote R, et al
    International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.
    BJU Int. 2024;134:932-938.
    PubMed     Abstract available
    
    
    
79. GUO AA, Zeng K, Bushati Y, Kim P, et al
    Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta-analysis.
    BJU Int. 2024;134 Suppl 2:22-29.
    PubMed     Abstract available
    
    
    
80. AKDEMIR E, Stuiver MM, van de Kamp MW, der Hulst JB, et al
    Long-term quality of life in patients with bladder cancer following radical cystectomy.
    BJU Int. 2024 Dec 1. doi: 10.1111/bju.16610.
    PubMed     Abstract available
    
    
    November 2024
81. LONE Z, Shin D, Nowacki A, Campbell RA, et al
    Body morphometry may predict parastomal hernia following radical cystectomy with ileal conduit.
    BJU Int. 2024;134:841-847.
    PubMed     Abstract available
    
    
    
82. DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
    A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
    BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572.
    PubMed     Abstract available
    
    
    October 2024
83. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
    BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
    PubMed     Abstract available
    
    
    
84. GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
    Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.
    BJU Int. 2024 Oct 21. doi: 10.1111/bju.16565.
    PubMed     Abstract available
    
    
    
85. DEL GIUDICE F, Vestri A, Fegatelli DA, Husch T, et al
    VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.
    BJU Int. 2024 Oct 13. doi: 10.1111/bju.16531.
    PubMed     Abstract available
    
    
    
86. MAISCH P, Hwang EC, Kim K, Narayan VM, et al
    Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review.
    BJU Int. 2024;134:541-550.
    PubMed     Abstract available
    
    
    
87. RIEGER C, Schluchtermann J, Storz E, Kastner L, et al
    Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.
    BJU Int. 2024;134:582-588.
    PubMed     Abstract available
    
    
    September 2024
88. CONROY S, Jubber I, Noon AP, Rosario DJ, et al
    Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.
    BJU Int. 2024 Sep 26. doi: 10.1111/bju.16516.
    PubMed     Abstract available
    
    
    
89. LIU K, Nicoletti R, Zhao H, Chen X, et al
    The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
    BJU Int. 2024 Sep 10. doi: 10.1111/bju.16493.
    PubMed     Abstract available
    
    
    
90. VACCARO C, Dewulf K, Richter K, Branger N, et al
    Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique.
    BJU Int. 2024;134:501-503.
    PubMed    
    
    
    
91. ZENNAMI K, Kusaka M, Tomozawa S, Toda F, et al
    Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion.
    BJU Int. 2024;134:426-433.
    PubMed     Abstract available
    
    
    
92. D'ANDREA D, Soria F, Moschini M, Laukhtina E, et al
    Addition of neoadjuvant chemotherapy to a 'quadrifecta' composite in radical cystectomy.
    BJU Int. 2024;134:459-464.
    PubMed     Abstract available
    
    
    
93. AFFERI L, Spahn M, Hayoz S, Strebel RT, et al
    Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
    BJU Int. 2024;134:388-397.
    PubMed     Abstract available
    
    
    August 2024
94. SU ZT, Florissi IS, Mahon KM, Li T, et al
    Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Aug 29. doi: 10.1111/bju.16521.
    PubMed     Abstract available
    
    
    
95. TAYLOR JI, Kamat AM, O'Donnell MA, Annapureddy D, et al
    Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
    BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509.
    PubMed     Abstract available
    
    
    
96. HOLMBERG L, Skogmar S, Garmo H, Hagberg O, et al
    Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
    BJU Int. 2024;134:229-238.
    PubMed     Abstract available
    
    
    
97. MATSUDA A, Taoka R, Miki J, Saito R, et al
    Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
    BJU Int. 2024;134:207-218.
    PubMed     Abstract available
    
    
    July 2024
98. CHAKRA MA, Lassila R, El Beayni N, Mott SL, et al
    Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naive non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
    BJU Int. 2024 Jul 31. doi: 10.1111/bju.16486.
    PubMed     Abstract available
    
    
    
99. REMMELINK MJ, Rip Y, Nieuwenhuijzen JA, Ket JCF, et al
    Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.
    BJU Int. 2024 Jul 17. doi: 10.1111/bju.16471.
    PubMed     Abstract available
    
    
    
100. ANTONELLI L, Wendel-Garcia PD, Deforth M, Afferi L, et al
     Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
     BJU Int. 2024 Jul 3. doi: 10.1111/bju.16444.
     PubMed     Abstract available
     
     
     
101. 
     Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
     BJU Int. 2024;134:4-5.
     PubMed    
     
     
     
102. PELLEGRINO F, Scilipoti P, Rosiello G, Longoni M, et al
     Long-term functional outcomes after robot-assisted radical cystectomy with intracorporeal ileal orthotopic neobladder.
     BJU Int. 2024;134:48-50.
     PubMed    
     
     
     
103. TUDERTI G, Mastroianni R, Anceschi U, Bove AM, et al
     Learning curve for intracorporeal robotic Padua ileal bladder: 10-year functional assessment from a high-volume single-centre series.
     BJU Int. 2024;134:103-109.
     PubMed     Abstract available
     
     
     
104. MYERS AA, Tan WS, de Groot J, Westney OL, et al
     'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder.
     BJU Int. 2024;134:45-47.
     PubMed    
     
     
     
105. TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
     Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
     BJU Int. 2024;134:43-44.
     PubMed    
     
     
     
106. AN X, Xue C, Chen M, Ni M, et al
     Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
     BJU Int. 2024;134:63-71.
     PubMed     Abstract available
     
     
     June 2024
107. WOLFF I, Kravchuk AP, Wirtz RM, Schlomm T, et al
     Real-world performance of Uromonitor(R) in urothelial bladder cancer detection: a multicentric trial.
     BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450.
     PubMed     Abstract available
     
     
     
108. FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
     Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
     BJU Int. 2024 Jun 24. doi: 10.1111/bju.16440.
     PubMed     Abstract available
     
     
     
109. PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
     How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
     BJU Int. 2024;133:673-677.
     PubMed    
     
     
     May 2024
110. FINOCCHIARO A, Paciotti M, Contieri R, Fasulo V, et al
     Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?
     BJU Int. 2024 May 22. doi: 10.1111/bju.16406.
     PubMed    
     
     
     
111. HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
     Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
     BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
     PubMed     Abstract available
     
     
     April 2024
112. BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
     Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
     BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
     PubMed     Abstract available
     
     
     
113. SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
     Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
     BJU Int. 2024 Apr 24. doi: 10.1111/bju.16364.
     PubMed     Abstract available
     
     
     
114. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
     Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
     BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
     PubMed     Abstract available
     
     
     
115. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
     Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
     BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
     PubMed     Abstract available
     
     
     
116. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
     Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
     BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
     PubMed     Abstract available
     
     
     
117. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
     Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
     BJU Int. 2024;133:474-479.
     PubMed     Abstract available
     
     
     
118. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
     Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
     BJU Int. 2024;133 Suppl 4:53-63.
     PubMed     Abstract available
     
     
     
119. BOTROS A, Rival PM, Page F, Davis ID, et al
     Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
     BJU Int. 2024;133 Suppl 4:7-10.
     PubMed    
     
     
     March 2024
120. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
     Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
     BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
     PubMed     Abstract available
     
     
     
121. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
     The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
     PubMed     Abstract available
     
     
     
122. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
     The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
     PubMed     Abstract available
     
     
     February 2024
123. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
     A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
     BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
     PubMed     Abstract available
     
     
     
124. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
     Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
     BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
     PubMed     Abstract available
     
     
     
125. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
     Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
     BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
     PubMed     Abstract available
     
     
     
126. 
     Significant advances in chemotherapy for both urothelial and renal cancer.
     BJU Int. 2024;133:122-123.
     PubMed    
     
     
     
127. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
     Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
     BJU Int. 2024;133:154-157.
     PubMed    
     
     
     January 2024
128. LU SM, Zhang Y, Dong XT, Wang JL, et al
     Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
     BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
     PubMed    
     
     
     
129. YIM A, Alberto M, Sharma V, Green A, et al
     Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
     BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
     PubMed     Abstract available
     
     
     December 2023
130. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
     Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
     BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
     PubMed     Abstract available
     
     
     
131. HACK J, Douglas J, Makaroff L, Costin M, et al
     Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
     BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
     PubMed    
     
     
     
132. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
     Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
     BJU Int. 2023;132:671-677.
     PubMed     Abstract available
     
     
     November 2023
133. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
     Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
     BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
     PubMed     Abstract available
     
     
     
134. CHEDGY ECP, Tang R, Struss WJ, Lowe G, et al
     A randomized controlled trial investigating rectus sheath catheters following radical cystectomy.
     BJU Int. 2023;132:554-559.
     PubMed     Abstract available
     
     
     October 2023
135. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
     Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
     BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
     PubMed     Abstract available
     
     
     
136. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
     Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
     BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
     PubMed    
     
     
     
137. NECCHI A, Basile G, Gibb EA, Raggi D, et al
     VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
     BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
     PubMed     Abstract available
     
     
     
138. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
     Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
     BJU Int. 2023;132:428-434.
     PubMed     Abstract available
     
     
     September 2023
139. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
     Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
     BJU Int. 2023;132:291-297.
     PubMed     Abstract available
     
     
     August 2023
140. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
     Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
     BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
     PubMed     Abstract available
     
     
     July 2023
141. CONTIERI R, Grajales V, Tan WS, Martini A, et al
     Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
     BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
     PubMed     Abstract available
     
     
     
142. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
     Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
     BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
     PubMed     Abstract available
     
     
     
143. 
     Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
     BJU Int. 2023;132:2-3.
     PubMed    
     
     
     
144. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
     Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
     BJU Int. 2023;132:84-91.
     PubMed     Abstract available
     
     
     June 2023
145. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
     Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
     BJU Int. 2023;131:691-693.
     PubMed    
     
     
     
146. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
     Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
     BJU Int. 2023;131:734-744.
     PubMed     Abstract available
     
     
     
147. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
     Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
     BJU Int. 2023;131:755-762.
     PubMed     Abstract available
     
     
     
148. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
     Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
     BJU Int. 2023;131:712-719.
     PubMed     Abstract available
     
     
     May 2023
149. TAN WS, Grajales V, Bree K, Li R, et al
     BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
     BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
     PubMed    
     
     
     
150. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
     Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
     BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
     PubMed     Abstract available
     
     
     
151. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
     Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
     BJU Int. 2023;131:571-580.
     PubMed     Abstract available
     
     
     April 2023
152. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
     Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
     BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
     PubMed    
     
     
     
153. FREGO N, Contieri R, Diana P, Mancon S, et al
     Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
     BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
     PubMed    
     
     
     
154. ROSE KM, Narang G, Rosen G, Labatte C, et al
     Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
     BJU Int. 2023;131:471-476.
     PubMed     Abstract available
     
     
     
155. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
     Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
     BJU Int. 2023;131:477-485.
     PubMed     Abstract available
     
     
     March 2023
156. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
     Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
     BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
     PubMed     Abstract available
     
     
     
157. BESIROGLU H
     Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
     BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
     PubMed    
     
     
     
158. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
     Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
     BJU Int. 2023;131:306-312.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum